Rating Change
Chardan Capital analysts reiterated a Buy rating on Ocular Therapeutix, Inc. (NASDAQ:OCUL) on August 04, 2026.
reiterateNASDAQ:OCUL
Chardan Capital Reiterates Buy Rating on Ocular Therapeutix, Inc. (OCUL)
Rating Change Chardan Capital analysts reiterated a Buy rating on Ocular Therapeutix, Inc. (NASDAQ:OCUL) on August 04, 2026. Market Context Ocular Therapeutix, Inc.
Market Context
Ocular Therapeutix, Inc. operates in the Healthcare sector. The stock currently trades at $8.55 with a market capitalization of $2.5B.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ocular Therapeutix, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ocular Therapeutix, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 04, 2026 | Chardan Capital | Buy | N/A |
| Jun 25, 2026 | Chardan Capital | Buy | N/A |
| Jun 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 18, 2026 | Baird | Outperform | N/A |
| May 06, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View OCUL Stock Page
Frequently Asked Questions
What does a Buy rating mean for OCUL?
A Buy rating from Chardan Capital reflects the analyst's outlook on Ocular Therapeutix, Inc. (NASDAQ:OCUL). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the OCUL forecast page.
